Pfizer Inc. (NYSE:PFE) Shares Sold by 1900 Wealth Management LLC

1900 Wealth Management LLC trimmed its position in Pfizer Inc. (NYSE:PFE) by 10.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 27,729 shares of the biopharmaceutical company’s stock after selling 3,157 shares during the period. 1900 Wealth Management LLC’s holdings in Pfizer were worth $798,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Stephens Consulting LLC grew its position in Pfizer by 26.0% during the 4th quarter. Stephens Consulting LLC now owns 4,845 shares of the biopharmaceutical company’s stock worth $139,000 after purchasing an additional 1,000 shares during the period. RWA Wealth Partners LLC boosted its stake in shares of Pfizer by 198.5% during the 4th quarter. RWA Wealth Partners LLC now owns 291,324 shares of the biopharmaceutical company’s stock worth $8,387,000 after acquiring an additional 193,726 shares in the last quarter. Mengis Capital Management Inc. boosted its stake in shares of Pfizer by 0.9% during the 4th quarter. Mengis Capital Management Inc. now owns 63,650 shares of the biopharmaceutical company’s stock worth $1,833,000 after acquiring an additional 550 shares in the last quarter. GUNN & Co INVESTMENT MANAGEMENT INC. purchased a new stake in shares of Pfizer during the 4th quarter worth about $2,601,000. Finally, Capital Investment Advisory Services LLC boosted its stake in shares of Pfizer by 12.5% during the 4th quarter. Capital Investment Advisory Services LLC now owns 98,200 shares of the biopharmaceutical company’s stock worth $2,827,000 after acquiring an additional 10,931 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the stock. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. TD Cowen lowered shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target on the stock. in a research note on Thursday, January 4th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research note on Monday, April 15th. Finally, Guggenheim initiated coverage on shares of Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target on the stock. Eleven equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $36.33.

Pfizer Stock Performance

PFE traded up $0.11 on Tuesday, reaching $26.37. The company had a trading volume of 7,416,015 shares, compared to its average volume of 41,878,773. Pfizer Inc. has a 1 year low of $25.23 and a 1 year high of $40.37. The stock has a market capitalization of $149.32 billion, a PE ratio of 73.28, a P/E/G ratio of 1.17 and a beta of 0.61. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. The stock has a 50-day moving average price of $27.08 and a 200-day moving average price of $28.56.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. The firm had revenue of $14.25 billion during the quarter, compared to analysts’ expectations of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. Pfizer’s quarterly revenue was down 41.3% compared to the same quarter last year. During the same period in the previous year, the company earned $1.14 earnings per share. As a group, research analysts forecast that Pfizer Inc. will post 2.24 EPS for the current fiscal year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.